id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-1977-N-0049-0003,FDA,FDA-1977-N-0049,List of References [FDA-1977-N-0049-0001],Supporting & Related Material,Background Material,2009-12-10T05:00:00Z,2009,12,,,2019-02-06T17:44:57Z,,0,0,0900006480a68e9e
FDA-1977-N-0049-0001,FDA,FDA-1977-N-0049,"Internal Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human Use; Proposed Amendment to the Tentative Final Monograph",Proposed Rule,Notice of Proposed Rulemaking (NPRM),2009-12-10T05:00:00Z,2009,12,2009-12-10T05:00:00Z,1992-04-23T03:59:59Z,2019-03-20T18:03:31Z,91-30424,0,0,09000064805da64d
FDA-1977-N-0049-0002,FDA,FDA-1977-N-0049,"Internal Memorandum from William E. Gilbertson (HFD-210) to Dockets Management Branch (HFA-305) December 24, 1991",Other,Memorandum,2009-12-10T05:00:00Z,2009,12,2009-12-10T05:00:00Z,,2019-02-07T14:57:56Z,,0,0,0900006480a68e9d